155 related articles for article (PubMed ID: 26392103)
21. Bexarotene treatment of late-stage mycosis fungoides and Sézary syndrome: development of extracutaneous lymphoma in 6 patients.
Bouwhuis SA; Davis MD; el-Azhary RA; McEvoy MT; Gibson LE; Knudsen JM; Kist JM; Pittelkow MR
J Am Acad Dermatol; 2005 Jun; 52(6):991-6. PubMed ID: 15928617
[TBL] [Abstract][Full Text] [Related]
22. Fatal Case of Primary Cutaneous Aggressive T-Cell Lymphoma Switching From a CD4+ to a CD8+ Phenotype: Progressive Disease With Bexarotene and Romidepsin Treatment.
Johnson WT; Leeman-Neill RJ; Patel P; Ho J; Grandinetti LM; Jedrych J; Craig FE
Am J Dermatopathol; 2016 Nov; 38(11):832-837. PubMed ID: 27322928
[TBL] [Abstract][Full Text] [Related]
23. Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas.
Vermeer MH; Tensen CP; van der Stoop PM; van Oostveen HW; Lund M; Scheper RJ; Willemze R
Arch Dermatol; 2001 Jul; 137(7):901-5. PubMed ID: 11453809
[TBL] [Abstract][Full Text] [Related]
24. Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression.
Saintes C; Saint-Jean M; Renaut JJ; Dréno B; Quéreux G
Br J Dermatol; 2015 Mar; 172(3):819-21. PubMed ID: 25113163
[No Abstract] [Full Text] [Related]
25. Brentuximab vedotin in CD30
Enos TH; Feigenbaum LS; Wickless HW
Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
[TBL] [Abstract][Full Text] [Related]
26. Expression of T-follicular helper markers in sequential biopsies of progressive mycosis fungoides and other primary cutaneous T-cell lymphomas.
Bosisio FM; Cerroni L
Am J Dermatopathol; 2015 Feb; 37(2):115-21. PubMed ID: 25406852
[TBL] [Abstract][Full Text] [Related]
27. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases.
Fauconneau A; Pham-Ledard A; Cappellen D; Frison E; Prochazkova-Carlotti M; Parrens M; Dalle S; Joly P; Viraben R; Franck F; Ingen-Housz-Oro S; Giacchero D; Jullié ML; Vergier B; Merlio JP; Beylot-Barry M
Br J Dermatol; 2015 Jun; 172(6):1547-1554. PubMed ID: 25645336
[TBL] [Abstract][Full Text] [Related]
28. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
29. Variability in the Expression of Immunohistochemical Markers: Implications for Biomarker Interpretation in Cutaneous T-Cell Lymphoma.
Rahbar Z; Li S; Tavallaee M; Novoa RA; Kim J; Kim YH
J Invest Dermatol; 2018 May; 138(5):1204-1206. PubMed ID: 29247659
[No Abstract] [Full Text] [Related]
30. Brentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.
Scarisbrick JJ
Future Oncol; 2017 Nov; 13(27):2405-2411. PubMed ID: 28805086
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous T-cell lymphoma's confounding nature.
Schmidt C
J Natl Cancer Inst; 2012 Jun; 104(11):806-8. PubMed ID: 22673589
[No Abstract] [Full Text] [Related]
32. Antibody-Based Therapies for Cutaneous T-Cell Lymphoma.
Welborn M; Duvic M
Am J Clin Dermatol; 2019 Feb; 20(1):115-122. PubMed ID: 30430444
[TBL] [Abstract][Full Text] [Related]
33. Clinical experience: practical management of five patients with cutaneous T-cell lymphoma (CTCL)-related symptoms.
Dummer R; Foss F; Dreno B; Bagot M
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S26-32. PubMed ID: 16516673
[TBL] [Abstract][Full Text] [Related]
34. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
35. Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides.
Talpur R; Sui D; Gangar P; Dabaja BS; Duvic M
Clin Lymphoma Myeloma Leuk; 2016 Jan; 16(1):49-56. PubMed ID: 26702474
[TBL] [Abstract][Full Text] [Related]
36. CD30 (Ki-1)-positive primary cutaneous T-cell lymphoma: report of spontaneous resolution.
Artemi P; Wong DA; Mann S; Regan W
Australas J Dermatol; 1997 Nov; 38(4):206-8. PubMed ID: 9431717
[TBL] [Abstract][Full Text] [Related]
37. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
[TBL] [Abstract][Full Text] [Related]
38. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
39. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
[TBL] [Abstract][Full Text] [Related]
40. Response of CD30+ large cell lymphoma of skin to bexarotene.
Keun YK; Woodruff R; Sangueza O
Leuk Lymphoma; 2002 May; 43(5):1153-4. PubMed ID: 12148901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
